The Institute for Clinical and Economic Review flagged five drugs whose prices were raised in 2023 with no evidence to ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Sabari, MD, which focused on the approval of amivantamab plus lazertinib in the first line, he looks ahead to potential uses ...